A Phase 3 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Takeda. Completed at 72 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-21.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.
Among the 10 studies testing vonoprazan in Esophagitis, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 5th registered.
123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.
Browse Esophagitis studies →1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 18+
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2015.
This study's enrollment of 703 is above the median of 96 across 99 interventional studies indexed under Esophagitis.
Median enrollment 357 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
11 studies in Esophagitis by Takeda: none open now, none under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 11 studies in Esophagitis by Takeda, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 7th registered.
Takeda’s Esophagitis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 11 in Esophagitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of vonoprazan to lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as to determine the clinically recommended dose for vonoprazan for maintenance therapy in erosive esophagitis.
The drug being tested in this study is called vonoprazan. Vonoprazan is being tested as a maintenance treatment for people with healed erosive esophagitis (EE). This study will look at participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of vonoprazan to Lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as to determine the clinically recommended dose for vonoprazan for maintenance therapy in erosive esophagitis.
The study will enroll approximately 693 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
Participants with ongoing erosive esophagitis (EE) will receive lansoprazole 30 mg once daily for 4 or 8 weeks (the Healing phase) until healing of EE is confirmed by endoscopy performed at either Week -4 and/or Day 1 before eligible for randomization to maintenance phase. In Maintenance phase, participants with confirming EE healing will be asked to take 2 tablets and a capsule at the same time each morning after breakfast throughout the study. All participants will be asked to record daytime and nighttime (during sleep) subjective symptoms in a diary on a daily basis.
This multi-centre trial will be conducted worldwide. The overall time to participate in this study is 8 months. Participants will make multiple visits to the clinic, and will be contacted by telephone 7-14 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Laboratory tests performed on visit 1 revealed any of the following abnormalities in the participant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE. Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing.
Drug: Vonoprazan · Drug: Lansoprazole · Drug: Vonoprazan Placebo · Drug: Lansoprazole Placebo
Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE. Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing
Drug: Vonoprazan · Drug: Lansoprazole · Drug: Vonoprazan Placebo · Drug: Lansoprazole Placebo
Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE. Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing.
Drug: Lansoprazole · Drug: Vonoprazan Placebo
Vonoprazan tablets
Also known as: TAK-438
Lansoprazole capsules or tablets
Also known as: Prevacid
Vonoprazan placebo-matching tablets
Lansoprazole placebo-matching capsules
Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase
Erosive esophagitis recurrence is defined as participants endoscopically confirmed to have erosive esophagitis (Los Angeles \[LA\] classification grades A to D) during the Maintenance Phase (24 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.
Time frame: 24 weeks
Percentage of Participants With Recurrence of Erosive Esophagitis After 12 Weeks of Treatment in the Maintenance Phase
Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades A to D) during the Maintenance Phase (12 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.
Time frame: 12 weeks
Number of Participants With Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.
Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Number of Participants With Abnormal Clinical Laboratory Findings
Clinical laboratory safety tests included chemistry, hematology and urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.
Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.
Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Number of Participants With Abnormal Vital Sign Measurements
The percentage of participants with any markedly abnormal vital sign measurements including (body temperature, blood pressure and pulse), mmHg = millimeters of mercury.
Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Change From Baseline in Serum Gastrin
Time frame: Baseline and Weeks 4, 12 and 24
Change From Baseline in Serum Pepsinogen I
Time frame: Baseline and Weeks 4, 12 and 24
Change From Baseline in Serum Pepsinogen II
Time frame: Baseline and Weeks 4, 12 and 24
Participants took part in the study at 64 investigative sites in China, Malaysia, South Korea, and Taiwan from 01 April 2015 to 31 December 2018.
| Milestone | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Started | 235 | 226 | 242 |
| Completed | 181 | 166 | 180 |
| Not completed | 54 | 60 | 62 |
| Withdrew: Pretreatment event/adverse event | 13 | 11 | 12 |
| Withdrew: Major protocol deviation | 18 | 25 | 22 |
| Withdrew: Lost to follow-up | 5 | 1 | 4 |
| Withdrew: Voluntary withdrawal | 10 | 18 | 17 |
| Withdrew: Lack of efficacy | 3 | 0 | 3 |
| Withdrew: Reason not specified | 5 | 5 | 4 |
Erosive esophagitis recurrence is defined as participants endoscopically confirmed to have erosive esophagitis (Los Angeles \[LA\] classification grades A to D) during the Maintenance Phase (24 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.
| percentage of participants | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase | 13.3 (8.684 to 19.084) | 12.3 (7.765 to 18.158) | 25.5 (19.412 to 32.481) |
Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades A to D) during the Maintenance Phase (12 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.
| percentage of participants | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Percentage of Participants With Recurrence of Erosive Esophagitis After 12 Weeks of Treatment in the Maintenance Phase | 27.8 (9.695 to 53.480) | 10.0 (1.235 to 31.698) | 35.0 (15.391 to 59.219) |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.
| Participants | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 157 | 156 | 158 |
Clinical laboratory safety tests included chemistry, hematology and urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.
| Participants | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Hematology: Red Blood Cells (>1.2xULN) | 1 | 0 | 1 |
| Hematology: White Blood Cells (>1.5xULN) | 0 | 0 | 1 |
| Hematology: Hemoglobin (<0.8xLLN) | 1 | 1 | 1 |
| Hematology: Hematocrit (<0.8xLLN) | 0 | 1 | 1 |
| Hematology: Platelets (<75x10^9/L) | 0 | 1 | 0 |
| Hematology: Neutrophils (<0.5xLLN) | 1 | 0 | 0 |
| Hematology: Eosinophils (>2xULN) | 2 | 2 | 0 |
| Hematology: Lymphocytes (>1.5xULN) | 1 | 0 | 0 |
| Serum Chemistry: ALT (>3xULN) | 1 | 1 | 0 |
| Serum Chemistry: AST (>3xULN) | 2 | 0 | 2 |
| Serum Chemistry: GGT (>3xULN) | 4 | 2 | 7 |
| Serum Chemistry: CK (CPK) (>5xULN) | 4 | 2 | 3 |
| Serum Chemistry: Albumin (<25 g/L) | 0 | 0 | 1 |
| Serum Chemistry: Creatinine (>177 umol/L) | 0 | 0 | 1 |
| Serum Chemistry: BUN (>10.7 mmol/L) | 2 | 4 | 2 |
| Serum Chemistry: Uric Acid (>0.773 mmol/L) | 0 | 1 | 0 |
| Serum Chemistry: Total Cholesterol (>7.72 mmol/L) | 2 | 5 | 3 |
| Serum Chemistry: Triglycerides (>2.5xULN) | 2 | 5 | 6 |
| Serum Chemistry: Glucose (<2.8 mmol/L) | 1 | 0 | 1 |
| Serum Chemistry: Glucose (>19.4 mmol/L) | 1 | 0 | 0 |
| Serum Chemistry: Potassium (<3.0 mmol/L) | 0 | 0 | 1 |
| Serum Chemistry: Sodium (>150 mmol/L) | 1 | 0 | 0 |
| Serum Chemistry: Vitamin B12 (<92 pmol/L) | 1 | 0 | 3 |
Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.
| Participants | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Heart Rate (<50 bpm) | 8 | 7 | 4 |
| Heart Rate (>120 bpm) | 0 | 1 | 0 |
| QT Interval (>=460 msec) | 9 | 5 | 8 |
| QTcF Interval (>= 500, or >= 450 with CHG >= 30) | 8 | 3 | 6 |
The percentage of participants with any markedly abnormal vital sign measurements including (body temperature, blood pressure and pulse), mmHg = millimeters of mercury.
| Participants | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Body Temperature (<35.6 °Celsius) | 6 | 3 | 12 |
| Body Temperature (>37.7 °Celsius) | 0 | 1 | 0 |
| Systolic Blood Pressure (<85 mmHg) | 2 | 0 | 0 |
| Diastolic Blood Pressure (<50 mmHg) | 0 | 2 | 1 |
| Diastolic Blood Pressure (>110 mmHg) | 1 | 0 | 0 |
| Pulse (<50 bpm) | 1 | 4 | 3 |
| Pulse (>120 bpm) | 1 | 1 | 0 |
| pmol/L | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Baseline | 20.42 ± 33.969 | 17.97 ± 21.458 | 21.94 ± 27.905 |
| Change at Week 4 | 10.09 ± 37.747 | 22.76 ± 36.053 | -11.21 ± 24.651 |
| Change at Week 12 | 14.45 ± 29.439 | 31.92 ± 45.127 | -8.76 ± 24.578 |
| Change at Week 24 | 17.47 ± 39.847 | 37.60 ± 47.172 | -7.41 ± 22.210 |
| ug/L | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Baseline | 287.1 ± 249.41 | 276.3 ± 203.46 | 303.3 ± 253.76 |
| Change at Week 4 | 40.5 ± 266.92 | 139.8 ± 269.08 | -112.3 ± 245.22 |
| Change at Week 12 | -3.1 ± 267.65 | 89.9 ± 285.05 | -123.5 ± 252.45 |
| Change at Week 24 | 5.9 ± 289.91 | 55.4 ± 279.65 | -103.9 ± 218.80 |
| ug/L | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Baseline | 22.9 ± 22.42 | 22.1 ± 17.40 | 24.6 ± 23.83 |
| Change at Week 4 | 3.8 ± 27.34 | 16.5 ± 25.56 | -10.9 ± 23.98 |
| Change at Week 12 | -1.6 ± 24.02 | 9.0 ± 26.40 | -10.9 ± 24.41 |
| Change at Week 24 | -0.6 ± 27.23 | 5.8 ± 25.59 | -8.7 ± 19.61 |
Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vonoprazan 10 mg | 0/235 (0%) | 10/235 (4.3%) | 81/235 (34.5%) |
| Vonoprazan 20 mg | 0/226 (0%) | 8/226 (3.5%) | 79/226 (35%) |
| Lansoprazole 15 mg | 1/242 (0.4%) | 12/242 (5%) | 79/242 (32.6%) |
| Event | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Calculus uretericRenal and urinary disorders | 2/235 | 0/226 | 0/242 |
| Hypertensive heart diseaseCardiac disorders | 0/235 | 1/226 | 0/242 |
| Arthritis infectiveInfections and infestations | 0/235 | 1/226 | 0/242 |
| GastroenteritisInfections and infestations | 0/235 | 1/226 | 0/242 |
| Spinal column injuryInjury, poisoning and procedural complications | 0/235 | 1/226 | 0/242 |
| Gouty arthritisMusculoskeletal and connective tissue disorders | 0/235 | 1/226 | 0/242 |
| Gouty tophusMusculoskeletal and connective tissue disorders | 0/235 | 1/226 | 0/242 |
| Gastric adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/235 | 1/226 | 0/242 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/235 | 1/226 | 0/242 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/235 | 1/226 | 0/242 |
| Event | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 30/235 | 29/226 | 21/242 |
| DiarrhoeaGastrointestinal disorders | 15/235 | 21/226 | 17/242 |
| DyspepsiaGastrointestinal disorders | 18/235 | 10/226 | 12/242 |
| Alanine aminotransferase increasedInvestigations | 13/235 | 9/226 | 16/242 |
| Abdominal distensionGastrointestinal disorders | 5/235 | 6/226 | 13/242 |
| Gastric polypsGastrointestinal disorders | 11/235 | 12/226 | 8/242 |
| NasopharyngitisInfections and infestations | 12/235 | 12/226 | 11/242 |
Randomized set included all randomized participants. The number analyzed is the number of participants with data available for analysis
| Age, Continuous(years) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| Mean | 51.7 ± 11.79 | 52.8 ± 13.02 | 54.0 ± 12.80 | 52.8 ± 12.56 |
| Sex: Female, Male(Participants) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| Female | 59 | 61 | 64 | 184 |
| Male | 176 | 165 | 178 | 519 |
| Race (NIH/OMB)(Participants) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 235 | 225 | 242 | 702 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| China | 163 | 159 | 169 | 491 |
| Malaysia | 24 | 24 | 24 | 72 |
| Korea, Republic Of | 26 | 23 | 27 | 76 |
| Taiwan, Province Of China | 22 | 20 | 22 | 64 |
| Height(centimeter (cm)) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| Mean | 166.7 ± 8.35 | 166.1 ± 8.31 | 167.1 ± 8.01 | 166.7 ± 8.22 |
| Weight(kilogram (kg)) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| Mean | 70.03 ± 12.137 | 68.10 ± 11.314 | 69.19 ± 11.075 | 69.12 ± 11.528 |
| Body Mass Index (BMI)(kg/m^2) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| Mean | 25.10 ± 3.449 | 24.58 ± 3.052 | 24.77 ± 3.475 | 24.82 ± 3.338 |
| Smoking Classification(Participants) | Vonoprazan 10 mg | Vonoprazan 20 mg | Lansoprazole 15 mg | Total |
|---|---|---|---|---|
| The Participant Has Never Smoked | 157 | 135 | 147 | 439 |
| The Participant Is a Current Smoker | 50 | 47 | 55 | 152 |
| The Participant Is an Ex-smoker | 28 | 44 | 40 | 112 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Apr 2015 to primary completion in Dec 2018, 44 months.
Results were first posted in Feb 2020, 1 year 1 month after primary completion.
Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 44 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan